Comments (34)

Most Helpful
  • Analyst 2 in IB - Cov
Nov 29, 2021 - 10:44pm

Healthcare banker at GS/JPM/BofA and have friends at 2 of the 3 groups you listed.

Jefferies: Healthcare is one of their best groups. Dealflow is extremely strong. They do a ridiculous number of healthcare services M&A deals, and also have a very solid biotech & biopharma practice. Their healthcare ECM practice is insane - at the height of the ECM craze this year they were doing something like 5 biotech IPOs and follow-ons every week. I've some friends there, and it seems like the group is an absolute sweatshop with some very old-school blue-blooded seniors (but the juniors are pretty fratty and chill). Exits there are also very good, a handful of MFs, and very solid placement into UMM and MM PE.

Barclays: Does very well in services, and is arguably the best BB in Healthcare IT. ECM dealflow and exposure is also solid. The hours there are pretty long, but the culture definitely seems to be solid (few sharp elbows, seniors actually care about you, junior people are chill). PE placement isn't the best out of Barclays groups (except for that year where the analysts were all unusually strong and placed lights out iykyk), but MF is possible and UMM/MM placements are very common.

Credit Suisse: Not one of the top groups there. They have a solid ECM practice driven by SPACs, which CS is all-around strong in, but their M&A practice is pretty weak. Don't know a lot about PE placement or culture there.

For overall Healthcare exposure, I'd say Jefferies = Barclays >> Credit Suisse. You'll get your modeling reps in, as both Jefferies and Barclays HC have solid M&A dealflow and do in-house M&A. If you care about ECM exposure (personally I find biotech ECM to be the sexiest part of my job), I'd go Jefferies. If not, I'd go Barclays for the culture.

If you just want PE, I'd go Barclays > Jefferies > Credit Suisse. From what I've seen, Barclays still edges out Jefferies in terms of PE placement. I have no clue about Credit Suisse, but I don't hear a lot about their placement so I assume they'd be last.

  • Analyst 2 in IB - Cov
Nov 29, 2021 - 11:30pm

Overall it's a solid group, but it's been being robbed of its top talent and is far from what it once was. The biotech and biopharma practice has been pretty spotty after losing some key seniors, but ECM dealflow is still decent. MedTech team has decent M&A dealflow and really good ECM deal flow. The Healthcare Services & IT practice is still solid, but used to be much better before a bunch of seniors left. I will say the analyst experience isn't the greatest because the M&A group holds the pen on most healthcare modeling. You certainly can get exposure to M&A modeling, but you definitely have to (1) be in good standing with your staffer and (2) be very proactive about it. Hours are quite bad, but overall culture isn't too bad. There's constant work and pitching, but overall everyone in the group is quite nice. Seniors are relentless with giving you work, but they act human and aren't that sharp-elbowed. The juniors are all pretty close and extremely nice people, which makes the hours much more bearable. Turnover's been pretty high though (due to hours). Exits are decent, not the best from BofA, but not the worst. placement into UMM and MM is decent, but MF is definitely a lot harder than other groups at BofA.

Overall, personally I'd take Barclays and Jefferies over BofA HC, especially since Barclays and Jefferies do in-house modeling, which is something that I personally weigh a lot.

  • Analyst 1 in IB - Cov
Nov 30, 2021 - 3:26am

It's still Credit Suisse no? You are at least a BB bank. How bad can it be? Exists are still good like for UMM/MM PE or solid buy-side fund no? 

If CS doesn't get good exists, why are we in banking at all? EBs only recruit that many people a year, and the rest cannot just possibly go into the top 3 BB right?

  • Intern in IB-M&A
Nov 30, 2021 - 2:29pm

A few recent services deals I can think of: EQT/Integrated Clinical Oncology ($1.7B), Apax/Eating Recovery Center ($1.4B), Patient Square/Summit Healthcare ($1.3B), DFP Healthcare/Oncology Institute ($885M), CM Life Sciences/Mount Sinai ($2.8B), Centerbridge/Help at Home ($1.4B), Social Capital Holdings/Clover Health ($4.1B).

  • Analyst 1 in IB-M&A
Nov 30, 2021 - 1:20pm

UBS Healthcare is definitely one of the weaker groups there. Pre-2009 exodus they were a top 3 healthcare group on the street though. 

  • Analyst 1 in IB - Cov
Dec 2, 2021 - 1:38pm

Just curious but where would y'all put SVB Leerink in comparison with UBS/Barclays/Jefferies?

  • Intern in IB - Gen
Dec 15, 2021 - 11:39am

Had a call with an analyst at Jeff HC that I was close with when in college, and he straight up told me that his hours are insane, he was like be really sure you want to work here. 

  • Assist. VP in Legal
Dec 15, 2021 - 1:22pm

That's why BB HC groups seem to fluctuate so much in quality of deal flow because of boutique exits from senior bankers. Pretty sure Credit Suisse experienced something very similar when their BSD MD left for CVP (Stuart Smith was the #1 dealmaker on the street in 2011 and has been on a ton of marquee deals). Had a strong MD or two I believe leave to Guggenheim soon after as well.

  • Analyst 1 in IB - Gen
Dec 15, 2021 - 8:27pm

Et nobis veritatis aliquam dolor. Enim qui nihil ullam laudantium recusandae. Sed quisquam aut ut similique voluptatem. Voluptatem non minima molestiae quasi. Quia officia consequatur quasi distinctio. Dignissimos fugiat at est quidem eaque natus.

Dolor dicta et ut. Esse fugit sint aliquid a dicta. Odit dolores est sed recusandae. Porro quia adipisci accusantium expedita accusantium dolorum qui aliquam. Nam nobis corrupti nostrum sit.

Consequatur odit eligendi aut ipsum quae. Occaecati illo porro aut inventore placeat iusto.

  • Analyst 2 in IB - Cov
Dec 21, 2021 - 3:15pm

Quod consectetur quidem repudiandae rerum dignissimos. Reprehenderit ea quia sed nulla. Quis quam temporibus et voluptatem.

Quaerat fuga quisquam culpa dolore natus. Numquam ducimus ipsam id nihil magnam ut qui. Ea est et saepe omnis quaerat cum dolorem. Eos iste officiis commodi. Quas in corporis veniam. Sint id molestiae dolores harum.

Ut repellendus consequuntur quia at asperiores debitis earum. Laudantium fuga facere facilis aut qui quidem. Odit sunt et asperiores deleniti velit aliquam enim quisquam. Ipsa iusto aliquid error sint.

Start Discussion

Total Avg Compensation

January 2022 Investment Banking

  • Director/MD (5) $604
  • Vice President (20) $379
  • Associates (142) $239
  • 2nd Year Analyst (84) $153
  • 3rd+ Year Analyst (15) $150
  • 1st Year Analyst (291) $142
  • Intern/Summer Associate (63) $143
  • Intern/Summer Analyst (223) $89